In-vitro activities of essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: A multi-centre study in China, 2021

作者：Yun Wu, Jiawei Chen, Ge Zhang, Jin Li, Tong Wang, Wei Kang, Jingjia Zhang, Hongli Sun, Yali Liu, Yingchun Xu · 发表于：International Journal of Antimicrobial Agents · 年份：2024 · DOI：10.1016/j.ijantimicag.2024.107341 · 被引用次数：32 · 研究领域：Antibiotic Resistance in Bacteria、Antibiotics Pharmacokinetics and Efficacy、Antibiotic Use and Resistance

• The isolation rates of carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) were 6.31% (332/5265), 62.95% (440/699) and 15.20% (152/1000), respectively. Aztreonam/avibactam, colistin and eravacycline exhibited high antimicrobial activity against different species producing various carbapenemases. • The two highest isolation rates for CRPA were found in respiratory and central nervous system (CNS) infections. For CRAB, the highest isolation rate was in CNS infections, followed by bloodstream infections, and skin and soft tissue infections. For CRE, the highest isolation rates were in CNS infections and urinary tract infections. • In CRE, aztreonam/avibactam exhibited higher antimicrobial activity than ceftazidime/avibactam. However, in CRPA, aztreonam/avibactam showed lower antibacterial activity than ceftazidime/avibactam. In a comparison of antimicrobial activity between tigecycline and eravacycline, eravacycline maintained higher antimicrobial activity in CRE and CRAB. • The association between different resistance mechanisms and antimicrobial activity was analysed, which is less commonly addressed in existing research. Carbapenem-resistant bacteria (CRB), including carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA) and carbapenem-resistant Enterobacterales (CRE), pose a considerable threat to public health in China. Erava...